- Romark is conducting clinical trials and seeking worldwide marketing and emergency use authorizations for a novel host-directed antiviral therapeutic for COVID-19 to address emerging variants and play an important role in returning to normal functioning of society.   TAMPA, Fla. – March 9, 2022 – Romark announced today that results of its Vanguard Co-V clinical

- NT-300 reduced progression to severe COVID-19 disease by 85% - Romark is working with FDA and plans to seek Emergency Use Authorization in the U.S. TAMPA, Fla. – April 14, 2021 – Romark announced today initial results of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300 mg)

TAMPA, Fla. - August 20, 2020 – Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in Manati, Puerto Rico for the production of ALINIA® (nitazoxanide)

NT-300 clinical program now comprises three pivotal trials for COVID-19   TAMPA, Fla. – August 11, 2020 – Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today the initiation of a Phase 3 clinical trial of its investigational new drug

Clinical Development Program for NT-300 Includes Trials Addressing Prevention and Treatment of COVID-19 and Other Viral Respiratory Illnesses   TAMPA, Fla. – April 27, 2020 – Romark announced today it will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk